Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 3/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8669891 | 1.00 | ALDH1A1 (0.64) | ALDH1A1ACP3L3MBTL1KMT2AMEN1 | |
| SCHEMBL8666394 | 1.00 | ALDH1A1 (0.64) | ALDH1A1ACP3L3MBTL1KMT2AMEN1 | |
| SCHEMBL5042702 | 0.87 | ALDH1A1 (0.62) | ALDH1A1ACP3L3MBTL1KMT2AMEN1 | |
| SCHEMBL1095030 | 0.84 | ATM (0.55) | ALDH1A1ACP3L3MBTL1KMT2AMEN1 | |
| SCHEMBL6676859 | 0.84 | ALDH1A1 (0.59) | ALDH1A1ACP3L3MBTL1KMT2AMEN1 | |
| SCHEMBL2191046 | 0.83 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1KMT2AMEN1HPGD | |
| SCHEMBL2387750 | 0.81 | KMT2A (0.54) | ALDH1A1L3MBTL1KMT2AMEN1HPGD | |
| SCHEMBL8582041 | 0.80 | AKR1C3 (0.67) | ALDH1A1ACP3L3MBTL1KMT2AMEN1 | |
| SCHEMBL307016 | 0.80 | AKR1C3 (0.67) | ALDH1A1ACP3L3MBTL1KMT2AMEN1 | |
| SCHEMBL3992888 | 0.80 | AKR1C3 (0.67) | ALDH1A1ACP3L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| US-5756065-A | DIAGNOSTIC CHELATES FOR ANTIBODIES AND RADIOACTIVE MATERIALS | THE DOW CHEMICAL COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5707991-A | TREATMENT OF NERVOUS SYSTEM DISORDERS, PARKINSON'S DISEASE | RHONE-POULENC RORER S.A. (FR) | 1998-01-13 | — | — | US | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
| US-5652361-A | ANTITUMOR | THE DOW CHEMICAL COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| US-5435990-A | Chelate-antibody complexes, treatment and diagnosis of cancer, tetraazacyclododecane compounds | THE DOW CHEMICAL COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0353450-B1 | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates | DOW CHEMICAL CO (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0420942-A1 | MACROCYCLIC BIFUNCTIONAL CHELANTS, COMPLEXES THEREOF AND THEIR ANTIBODY CONJUGATES | THE DOW CHEMICAL COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
| EP-0353450-A1 | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates | THE DOW CHEMICAL COMPANY (US) | 1990-02-07 | — | — | EP | disclosed |
| WO-1989012631-A1 | MACROCYCLIC BIFUNCTIONAL CHELANTS, COMPLEXES THEREOF AND THEIR ANTIBODY CONJUGATES | THE DOW CHEMICAL COMPANY (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | ALDH1A1 519/4885ACP3 1943/4885L3MBTL1 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.